2019 Cannabis Business Award's Publication of the Year |
THURSDAY, DECEMBER 25, 2025 |
FMCPG HAS BEEN SERVING AND REPRESENTING THE CANNABIS PHYSICIAN COMMUNITY
SINCE 2020 |
THE "FLORIDA MEDICAL CANNABIS PHYSICIAN GROUP" (FMCPG) FOR ALL
"MEDICAL MARIJUANA DOCTORS" AND "MMTC DIRECTORS ONLY " SPECIAL GUEST:
JODI JAMES - FL CAN UPDATE FROM TALLAHASSEE MICHAEL BARENBOYM - WEEDGETS
DISCUSS AND UPDATE THE LEGISLATIVE PRIORITIES FOR 2025/2026 REVIEW OF THE OMMU AND CHANGES TO THE DOCTOR'S AND PATIENT INPUT PORTALS ON THE OMMU WEBSITE.
DOCTORS WITHIN OUR GROUP WILL DISCUSS HOW THEY HAVE BEEN WORKING AROUND SOME OF THE CHANGES
REF'S ISSUES AND SOLUTIONS TIME TO RENEW YOUR MEMBER IN FMCPG
CLICK HERE FOR THE MEMBERSHIP FORM USE THIS LINK TO REGISTER FOR THE NEXT MEETING - WEDNESDAY, JANUARY 14, 2026 CLICK ON LINK BELOW |
MEDICAL CANNABIS PHYSICIAN PROMOTION PACKAGE FOR 2026 BY CANNABIS NEWS FLORIDA
ARTICLE: Physician will contribute an article of 350 words**. This article will appear in the Cannabis News Florida e-newsletter for one month (4 weeks).
E-MAIL BLAST: Cannabis News Florida will send out one e-mail blast promoting the Physician to the other physicians in three zip code areas or one city to be determined by the Physician. The Physician will supply the information for the email blast. The Article above can be used in the e-mail blast.
The cost of this program is ONLY $399 AND INCLUDES A ONE YEAR MEMBERSHIP IN THE FMCPG - MUST BE PUCHASED BEFORE 12/31/25 **Cannabis News Florida will assign a writer for a telephone interview with the Physician and create the article to be published. Physician shall have the right to review and approve the article before publication for an additional cost of $100. IF YOU ARE INTERESTED, PLEASE EMAIL ME AT CHARLES@CANNABISNEWSFLORIDA.COM OR CALL MY CELL AT 954-605-4785 |
Why Weedgets Smoking Products Are Better for Your Lungs
When it comes to smoking, your lungs deserve protection—and that’s exactly what Weedgets products are designed to deliver. Unlike traditional pipes or joints that expose you to hot smoke and harsh particulates, Weedgets offers a cleaner, smoother, and safer smoking experience engineered for your respiratory health. Advanced Filtration for Cleaner Smoke At the heart of every Weedgets innovation is filtration technology. Weedgets pipes and accessories feature integrated micro-filters that trap impurities and resin particles before they reach your lungs. This significantly reduces exposure to tar, ash, and other combustion byproducts that can irritate your airways and cause coughing. The result is a noticeably cleaner inhale that feels light yet delivers full flavor and potency. Cooling the Smoke to Protect Your Airways
One of the biggest threats to lung comfort is the temperature of the smoke itself. Hot, unfiltered smoke can inflame the delicate tissue lining your respiratory tract. Weedgets addresses this with cooling pathways and diffusion systems that lower smoke temperature before it enters your mouth. By cooling each puff, these devices minimize throat burn and lung irritation, letting you enjoy a smoother and more comfortable session.
Designed for Moisture Retention and Hydration
Traditional smoking dries out your throat and lungs, often leading to post-session irritation. Weedgets’ designs—including the award-winning MAZE-X pipe—use moisture-preserving features that maintain a more balanced humidity level in each draw. This helps reduce dryness and supports the lungs’ natural ability to stay hydrated and clear.
Less Coughing, More Breathing Comfort Many users notice that Weedgets devices help them cough less and breathe more comfortably. That’s because the filtered and cooled smoke allows for deeper, more natural inhales without the harsh hit. Whether you’re a daily smoker or someone who values occasional sessions, Weedgets technology helps you enjoy the benefits of cannabis while protecting your respiratory wellness. Sustainable and Hygienic Design
Weedgets products are built for cleanability and reusability, unlike disposable filters or cheap pipes that accumulate residue and bacteria. Each component can be easily cleaned, ensuring a fresh and sanitary smoking experience every time. This not only supports better lung health but also contributes to a cleaner environment. Science-Driven Innovation Developed by engineers and health-conscious designers, Weedgets represents the future of responsible smoking. Every product is tested and refined to reduce the harmful effects of smoke inhalation while preserving the full sensory and therapeutic experience of cannabis.
In summary: Weedgets isn’t just about better smoking—it’s about smarter smoking. By filtering, cooling, and cleaning each puff, Weedgets protects your lungs so you can enjoy cannabis safely, comfortably, and consciously.
CLICK HERE FOR MORE INFORMATION |
NEWS FROM THE PAST WEEK RELATING TO THE BUSINESS OF
MMTC'S IN FLORIDA Click on Company Logo to be Transferred to Web Site |
Trulieve Applauds Trump Administration Decision To Reschedule Marijuana to Schedule III
Reclassification Eases Barriers to Research and Removes Punitive 280E Tax Burden
TALLAHASSEE, Fla., Dec. 18, 2025 — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., applauds action taken by the Trump Administration to reclassify marijuana to Schedule III under the Controlled Substances Act.
“This bold and historic direction from President Trump represents long overdue change and a major milestone in cannabis reform,” said Trulieve Chief Executive Officer Kim Rivers. “Trulieve is grateful for the decisive action taken by the Administration that acknowledges the medical benefits of cannabis, supports licensed and regulated operators, and allows law enforcement agencies to prosecute bad actors. We are committed to supporting the Administration throughout this process.”
Reclassification of marijuana to Schedule III does not legalize marijuana but it is an important first step in achieving practical common sense cannabis reform. Moving marijuana to Schedule III opens the door for more robust research of medical marijuana, removes the punitive tax burden imposed by Section 280E of the tax code, and retains flexibility for law enforcement to target and punish illicit operators.
READ MORE |
Trulieve Rewards Trulieve Rewards is a customer rewards program offering patients and customers in participating states an easy platform to earn points on every purchase at Trulieve dispensaries. We've revamped and refreshed our old cannabis loyalty program to reward cannabis enthusiasts loyal to Trulieve with savings, perks, and points every time they shop for cannabis products JOIN NOW |
The Cannabist Company Announces Agreement for the Sale of Virginia Assets to an Affiliate of Millstreet following Go-Shop
Announces Termination of its Previously Announced Agreement with Curaleaf
CHELMSFORD, Mass.—-Dec. 18, 2025– The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today announced that, following a go-shop process, it has entered into an agreement to sell all of the ownership interests of its subsidiary engaged in the business of cultivating, producing, manufacturing, distributing and selling cannabis in the Commonwealth of Virginia to an entity affiliated with Millstreet Credit Fund LP for total consideration of $130 million, subject to adjustment. The Virginia assets consist primarily of 5 active retail locations, 1 additional retail location in development, and approximately 82,000 square feet of cultivation and production capacity in the Richmond region.
READ MORE |
Cresco Labs CEO: Rescheduling Marks Historic Shift for Cannabis Industry
CHICAGO–December 18, 2025– Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump’s action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act.
“Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, acknowledging what millions of Americans already know: cannabis is medicine and deserves responsible, common-sense regulation.
This action starts bridging the gap between federal law and the will of the American people, with nearly 90 percent of Americans supporting some form of cannabis legalization and 74 percent already living in states with legal cannabis. Rescheduling unlocks opportunities for comprehensive medical research. It validates the work of state leaders who pioneered thoughtful, highly regulated cannabis programs for their constituents. It sends a strong message to our criminal justice system to stop imprisoning people for a plant that’s been used as medicine for more than 5,000 years.
READ MORE |
Verano Founder and Chief Executive Officer George Archos Shares Celebratory Comments on Cannabis Rescheduling Announcement
Verano’s active operations span 13 states, comprised of 158 dispensaries operating under the Zen Leaf™ and MÜV™ retail banners, and 15 cultivation and processing facilities with more than 1.1 million square feet of cultivation capacity
CHICAGO, Dec. 18, 2025 — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, celebrates today’s historic announcement that President Donald Trump has issued an Executive Order directing the Department of Justice to reschedule cannabis from Schedule I to Schedule III in the Controlled Substances Act, paving the way for potential reforms in the areas of medical research, banking, taxes, and the opportunity for Verano to list its shares on a U.S.-based stock exchange.
Quote from Verano Founder and Chief Executive Officer George Archos:
“Today’s historic cannabis rescheduling announcement marks a significant milestone and transformative policy shift that paves the way for America’s next great homegrown industry to finally reach its full potential by serving patients, creating jobs, unlocking economic growth, and reversing decades of harmful prohibitionist policies.
We’re grateful to President Trump for recognizing the overwhelming majority of Americans who support cannabis rescheduling, opening the door to federal reform, medical research, and normalization for an industry that employs hundreds of thousands of professionals and contributes billions of dollars in taxes and economic activity every year.
We look forward to the new opportunities rescheduling will provide cannabis businesses of all sizes, including critical banking and regulatory reforms that will unlock additional health, wellness, and economic benefits for communities nationwide.”
READ MORE
|
Planet 13 Urges Legislators and Regulators to Align with President Trump and Public Sentiment by Acting Decisively to Implement the Rescheduling Executive Order
Rescheduling Cannabis from Schedule I to Schedule III will help to foster a fair and supportive environment for the industry and reduce unnecessary obstacles to growth
LAS VEGAS, Dec. 22, 2025 — Planet 13 Holdings, Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, is sharing the following commentary regarding the December 18, 2025 Executive Order that directs the Attorney General to expedite completion of the process of rescheduling marijuana to Schedule III of the Controlled Substance Act.
Planet 13 remains committed to growth despite ongoing challenges related to banking, tax, and regulatory constraints, and the rescheduling announcement by the Trump Administration represents a positive development for job creation, industry growth and broader access to the potential medical benefits of cannabis.
Rescheduling cannabis from Schedule I to Schedule III may reduce certain tax constraints currently faced by the legal cannabis industry, including those related to IRS Code Section 280E. Rescheduling helps establish a foundation for future safe banking reforms. Safe banking in the cannabis industry provides a secure environment for financial transactions, granting access to essential services like checking accounts and loans. It ensures transparency, reduces costs associated with cash handling, and offers consumers safe and convenient payment options. Overall, safe banking is crucial for industry growth, regulatory compliance, and enhancing consumer experiences. Moreover, it would unlock substantial economic benefits, including job creation and increased tax revenues.
READ MORE |
Rescheduling = No 280E Taxes = More Cannabis Equity Raises and M&A Deals? The Viridian Chart of the Week looks at the Valuation impact of rescheduling eliminating 280E from a different viewpoint: the gap between the EBITDA multiples of Canadian LPs and US MSOs is largely due to the punitive effects of IRS Rule 280E on U.S.MSOs.
The orange line on the graph shows the multiples of enterprise value to next twelve-month EBITDA for the top Canadian LPs, while the blue line shows the same metric for the top U.S. MSOs. The green line shows the valuation multiple gap, now at 5.5 points, largely attributable to the fact that less U.S. EBITDA flows through to free cash flow due to 280E taxes. |
The elimination of 280E should allow U.S. multiples to exceed current Canadian multiples of 12.1x, since U.S. companies are generally more profitable, address much larger markets, and have additional positive catalysts from SAFER and other regulatory reforms. We believe U.S. multiples could more than double to 15x from their current value of 6.6x.
Higher valuations will transfer directly into higher M&A activity. Cash has been dear, and MSOs have been reluctant to use their equities as currency in acquisitions because such deals would be dilutive to their shareholders. Higher valuations will eliminate this problem, and the greater cash flows from lower taxes will also increase U.S. firms’ debt capacity. Both of these factors make acquisitions easier to finance and more accretive. The removal of 280E should also revive the cannabis equity capital markets, which have been in a virtual lockdown due to regulatory reform uncertainty. U.S. operators will seize the opportunity to repair their balance sheets through equity-based debt refinancing and equity-funded increases in capital spending. While we do not see valuations or activity springing back to the heady days of 2021, we expect significant upticks in activity compared to levels we have seen in the last two years.
For More Analysis View This Week’s Viridian Chart of the Week |
For More Analysis View This Week's Viridian Chart of the Week About Viridian Capital Advisors
Since launching in 2014, Viridian Capital Advisors has become one of the most respected and experienced advisory and M&A firms specializing in the cannabis industry. We provide a wide range of services, including:
Strategic Advisory Consulting: Including valuation, financial modeling, restructuring and fairness opinions. Mergers & Acquisitions: Transaction advisory and execution. Capital Raises: Including debt and equity. Many of our assignments begin with a basic question: "What should I do now?" Raise capital to expand? What kind of capital is most appropriate?
Acquire another company? What are the advantages and pitfalls? Sell my company? What valuations can i achieve? What transaction structures are possible?
Put our experience, data and depth of senior talent behind your next transaction.
Contact
Scott Greiper
CEO
Viridian Capital Advisors, LLC
646.330.0704
sgreiper@viridianca.com
Frank Colombo
Managing Director
Viridian Capital Advisors, LLC
914.523.4730
fcolombo@viridianca.com
|
NATIONAL AND INTERNATIONAL NEWS |
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas– December 22, 2025 – Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.
After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turning point carries profound meaning for companies that have remained committed to rigorous medical science.
CBIH Treasurer and Director, Mr. John Jones, noted that the company has experienced “the good, the difficult, and the indifferent,” yet has sustained its founding scientific vision despite intense headwinds. He highlighted that the rescheduling to Schedule III opens the door to conversations with pharmaceutical companies, strengthens dialogue with government officials regarding CBIH university medical cannabis programs, and accelerates the path for medical formulations and submitted patents currently under review.
READ MORE |
A New Era for Cannabis: Executive Order Launches Path to Schedule III – By Withum
Today, December 18, 2025, President Trump signed an Executive Order directing the Attorney General to expedite rescheduling marijuana to Schedule III under the Controlled Substances Act. This marks a historic shift in federal policy and sets the stage for significant changes in research, compliance and taxation.
Key points from the Executive Order
Rescheduling to Schedule III will recognize marijuana’s accepted medical use and remove major barriers to research. This is expected to rollout in the first half of 2026, barring possible delays by any legal challenges.
Expanded research initiatives will leverage real-world evidence to inform standards of care for medical marijuana and CBD products.
Improved access to hemp-derived cannabinoid products is a priority, with legislative and regulatory pathways under development.
What This Means for Your Business
Section 280E remains in effect for now.Until the DEA completes the rescheduling process and publishes a final rule, cannabis businesses cannot deduct ordinary business expenses on federal returns.
Retroactive amendments are not currently permitted.The Executive Order does not authorize retroactive application of Schedule III status or tax relief. Any changes will apply prospectively once the rule is finalized.
Compliance and planning:Begin preparing for a transition to Schedule III standards, including documentation of expenses and readiness for DEA/FDA oversight.
READ MORE |
Tilray Accelerates U.S. Medical Cannabis Expansion After Landmark Federal Rescheduling: Launches Tilray Medical USA to Lead Nationwide Medical Cannabis Innovation and Growth
Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare
NEW YORK, Dec. 18, 2025 — Tilray Medical, a division of Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis healthcare, today confirmed its planned strategic framework to advance its U.S. medical cannabis operations following federal cannabis rescheduling and related regulatory developments. In conjunction with these regulatory changes, Tilray announced the formation of Tilray Medical USA, Inc., further strengthening its commitment to leading medical cannabis innovation and growth. The Company’s approach is grounded in its proven track record operating at scale in regulated medical cannabis markets globally, supported by established compliance systems, scientific expertise, and disciplined governance. Tilray also issued the following statement in response to President Trump’s decision to reschedule cannabis.
Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, stated, “We support President Trump’s decision to reschedule cannabis as a constructive and necessary evolution of U.S. federal policy. This action aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity. It also signals a future shaped by innovation, responsible oversight, and evidence-based policy. We believe this landmark decision is a significant catalyst for positive change within the health, wellness, and business communities across the U.S. and a critical, incremental step toward descheduling and comprehensive regulation.”
READ MORE |
Blum Holdings, Inc. Announces Closing of Acquisition of High-Volume Bay Area Cannabis Retail Dispensary
Dec. 18, 2025 — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company, today announced the successful closing of its acquisition of a high-volume Bay Area cannabis retail dispensary through the purchase of all outstanding equity of the operating entity.
The acquired dispensary is a well-established, fully licensed retail operator located in a major Northern California market and has generated approximately $12.0 million in annual revenue with a long operating history and strong local customer base. The transaction further expands Blüm’s Northern California footprint.
“This acquisition reflects our continued focus on disciplined, opportunistic growth,” said Sabas Carrillo, Chief Executive Officer of Blüm Holdings. “We are acquiring durable retail assets with real revenue, real customers, and meaningful operating history, positioning the Company to benefit from both improved execution at the asset level and broader structural tailwinds impacting the U.S. cannabis industry.”
READ MORE | Optimi Health Announces Appointment of New Director
Vancouver, British Columbia– December 18, 2025 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the “Appointment“). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years. He currently serves as Senior Vice President and Partner at BFL Canada and has over a decade of experience providing tailored risk management and insurance solutions to clients in various industries, including manufacturing, distribution and life sciences.
READ MORE
|
BELOW ARE THE LINKS TO THE DIRECTORY OF FLORIDA CANNABIS DOCTORS AND
DISPENSARIES IN THE STATE OF FLORIDA |
QUALIFIED PATIENTS
OVER 930,000
AND 737 DISPENSING LOCATIONS |
LATEST OMMU REPORTS FROM OFFICE OF MEDICAL MARIJUANA USE IN THE STATE OF FLORIDA Highlights from
DECEMBER 19, 2025 Report BY THE NUMBERS
Qualified Patients: (Active ID Card) DEC 19 2025- 930,779 DEC 12 2025- 930,533
DEC 05 2025 930,643
NOV 28 2025 929,389
NOV 21 2025 929,916
NOV 14 2025 930,384
NOV 07 2025 931,117
Patients Last Week: +246
Qualified Ordering Physicians: 2,289 New Doctors Last Week: + 3 Reporting Period: DEC 12- DEC 17, 2025
Amount of Medical Marijuana Dispensed - (mgs THC) 432,236,206
Amount of Low-THC Cannabis Dispensed - (mgs CBD) 361
Amount of Marijuana in a From for Smoking (oz) 146,512.729
Approved Dispensing Locations: 737
Added Last Week: 3 Green Dragon - Yulee
Sunnyside - Tamarac The Flowery - Orange Park Closed Last Week - 1 Fluent - 1 |
UPCOMING MEETING AND CONFERENCES LOOK FOR IN FUTURE ISSUES |
ADVERTISEMENT OPPORTUNITIES
If your goal is to get your business in front of the right people in the cannabis industry or you want to be an integral part of this new and exciting business opportunity, then you need to join with Cannabis News Florida as we help to establish cannabis as a major part of the economy in Florida. Cannabis News Florida is an online publication focusing on both local and national news from leading authorities about the medical and business developments in the medical cannabis industry covering the entire state of Florida.
Join the Cannabis News Florida force online and in print. We offer several marketing options to fit all budgets:
· MMTC PROMOS LISTED IN EACH E-NEWSLETTER
• Directory Listing
• Banner Ads
• Ad Space in the Newspaper
• Feature Articles
• Weekly Newsletters
For further information or to make your ad reservation, please call:561-368-6950 / 954-605-4785 cell charles@cannabisnewsflorida.com
|
|
|